R

Roche

Global pharmaceuticals and diagnostics company

Kubernetes Infrastructure Reliability Engineer

Full-Time
No salary listed
Mid, Senior
Bachelor's, Master's
Madrid, Spain
In Person24/7 on-call rotation is required.
DevOps & InfrastructurePlatform Engineering

About the job

Requirements
  • 4–7 years of relevant experience without a degree, 2–5 years with a bachelor's degree, or 1–3 years with a master's degree.
  • At least 1 year of experience working in a multinational environment.
  • Strong hands-on experience navigating, managing, and hardening Kubernetes clusters and containers, including knowledge of distributed storage.
  • Hands-on experience delivering and managing infrastructure automation using Ansible and Terraform.
  • Proficiency in Python, Bash, or Go, including experience with test automation such as pytest and application programming interface deployment and management.
  • Expert knowledge of implementing software delivery pipelines using Jenkins, Rundeck, or GitLab.
  • Strong understanding of Linux operating systems and core networking principles, including DNS, load balancing, firewalls, routing, and service meshes.
  • Experience configuring logging, metrics, and monitoring tools, including setting up symptom-based alerts.
  • Experience with public cloud platforms, preferably Amazon Web Services, including managed compute, networking, security, and identity services such as EKS, VPC, and IAM.
  • Proven experience applying best practices in always-available service environments using Scrum and Agile methodologies.
  • Deep understanding of Technical Architecture Frameworks and quality and regulatory compliance standards.
  • Highly fluent oral and written English communication skills.
  • Ability to work across multiple time zones.
  • A 24/7 on-call rotation is required.
Responsibilities
  • Build and maintain Kubernetes-based infrastructure that enables modernization of business applications and processes.
  • Combine software and systems engineering to optimize systems, increase efficiency, and eliminate operational work through automation.
  • Deliver, maintain, and continuously improve a highly available Kubernetes platform across hybrid cloud deployments, including on-premise data centers and public clouds.
  • Apply software engineering principles to operations to build and run distributed, fault-tolerant systems with a focus on automation, security, and observability.
  • Perform capacity planning and launch reviews for services before they go live.
  • Perform blameless postmortems and proactively identify potential outages to drive iterative improvements.
  • Resolve complex problems in a global Kubernetes-based infrastructure by evaluating variable factors and inter-organizational impact.
  • Lead end-to-end infrastructure solution design and maintain component standards.
  • Evaluate solutions through proofs of concept and feasibility studies.
  • Serve as an internal escalation point for major incidents.
  • Bridge engineering and operations and present complex information and potential solutions to cross-functional teams and business stakeholders in non-technical terms.
  • Represent the organization as a primary contact on initiatives and interact with senior internal and external personnel.
  • Influence IT infrastructure vendor product evaluations and collaborate with IT partners to integrate feedback.
  • Mentor developers and promote DevOps practices for creating and deploying cloud-native applications.
  • Provide technical leadership and direction for small-to-medium-sized initiatives, projects, lifecycle work, and proofs of concept.
  • Ensure solutions comply with quality and regulatory standards and designs adhere to Technical Architecture Framework policies and directions.
  • Assist with planning technology projects, including estimating engineering resources, dependencies, risks, and timelines.
  • Apply extensive cloud-native technical expertise as a recognized Kubernetes expert.
Desired Qualifications
  • Certified Kubernetes Administrator certification.
  • Knowledge of Rancher or Portworx.
  • Healthcare industry experience.

About the company

Roche is a global leader in pharmaceuticals and diagnostics. It develops medicines and diagnostic tools that help detect, monitor, and treat diseases, using research and biotechnology to drive new therapies and tests. Roche combines drug development with in-house diagnostic products to support personalized medicine, where treatments are tailored to individual patients based on test results. Its approach differs from many peers by integrating drug discovery with diagnostic capabilities and by expanding its research through strategic acquisitions (like Genentech) to strengthen its biotechnology and R&D capabilities. The company’s goal is to improve patient outcomes and healthcare worldwide by delivering reliable medicines, accurate diagnostic tests, and data-driven care.

Company Size

1-10

Company Stage

IPO

Headquarters

Basel, Switzerland

Founded

1896

Get referred to Roche

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Enicepatide delivered 15.5% weight loss in September 2026 and 22.7% in June.
  • pTau217 can scale immediately through Roche's existing lab network and improve Alzheimer diagnostics.
  • Roche's June 2026 data and September 2026 filings signal multiple obesity shots on goal.

What critics are saying

  • Eli Lilly and Novo Nordisk dominate obesity pricing, distribution, and physician mindshare today.
  • Enicepatide remains Phase II-only; Roche starts late-stage glycemic and cardiovascular studies in 2027.
  • If enicepatide disappoints, Roche burns its $2.7 billion Carmot bet and loses obesity credibility.

What makes Roche unique

  • Roche combines pharma, diagnostics, and installed cobas labs across 4,500 U.S. instruments.
  • Elecsys pTau217 won FDA clearance on August 24, 2026, and CE marking September 7.
  • Roche controls obesity assets from Carmot and Zealand, spanning GLP-1/GIP and amylin.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Performance Bonus

Company News

Yahoo Finance
Oct 16th, 2026
FDA approves Roche's Enspryng as first at-home injection for thyroid eye disease

Roche said the US Food and Drug Administration (FDA) has approved Enspryng (satralizumab) for adults with thyroid eye disease (TED). It is the first and only at-home subcutaneous treatment for the condition, and a patient or caregiver can administer it after training. In the Phase III SatraGO-2 trial, 52.9% of active TED patients on Enspryng had a proptosis (eye bulging) response, against 23.4% on placebo. Double vision fell in 60.7% of patients, against 25.8%. The SatraGO-1 trial missed its primary endpoint at Week 24. No new safety signals emerged. TED affects about 155 in every 100,000 people in the US. This is Enspryng's second approval, after neuromyelitis optica spectrum disorder in 2020. The FDA is also reviewing it for myelin oligodendrocyte glycoprotein antibody-associated disease, with a decision expected in January 2027.

Yahoo Finance
Oct 9th, 2026
FDA approves Roche's Tecentriq for stage III colon cancer, cutting recurrence risk by 50%

The US Food and Drug Administration has approved Roche's Tecentriq in combination with a fluoropyrimidine and oxaliplatin for adjuvant treatment of stage III deficient DNA mismatch repair colon cancer. This marks Tecentriq's twelfth approved indication in the US. The approval follows the phase III ATOMIC study, published in The New England Journal of Medicine, which demonstrated that Tecentriq plus chemotherapy reduced the risk of disease recurrence or death by 50% compared to chemotherapy alone. The 36-month disease-free survival rate was 86% with the combination versus 76% with chemotherapy alone. Nearly 25% of colon cancers are diagnosed at stage III, and almost one in three stage III patients experience recurrence within five years. This represents the first approved adjuvant immunotherapy regimen for this patient population. Roche is pursuing further regulatory filings, including with the European Medicines Agency.

Yahoo Finance
Sep 30th, 2026
Roche's enicepatide shows 22.5% weight loss in 48 weeks, challenging Eli Lilly and Novo Nordisk

Roche posted strong Phase 2 results for its weight loss drug enicepatide, showing 22.5% mean weight loss over 48 weeks. This compares favourably to Eli Lilly's Zepbound, which achieved 20.2% weight loss over 72 weeks in a separate trial. In another Phase 2 study, enicepatide demonstrated HbA1c reductions of up to 2.65 percentage points in diabetic patients after 48 weeks, compared to tirzepatide's 2.37 percentage points after 52 weeks. Despite promising results, Roche faces stiff competition from Novo Nordisk and Eli Lilly, which both have deep pipelines in development. Novo Nordisk's CagriSema is nearing approval, whilst Eli Lilly's retatrutide has posted strong Phase 3 results. Roche's revenue grew 6% year over year in the first half of the year to 30.4 billion Swiss francs.

PR Newswire
Sep 30th, 2026
Roche launches newborn screening test for SMA, SCID and sickle cell disease

Roche has launched a newborn screening test that simultaneously detects three severe genetic conditions: Spinal Muscular Atrophy, Severe Combined Immunodeficiency Disease, and Sickle Cell Disease. TIB MOLBIOL, a Roche subsidiary, developed the LightMix Newborn TREC/SMN1/HBB kit for use in countries accepting the CE mark. The test enables early detection before symptoms appear, allowing clinicians to initiate life-changing treatments sooner. Early intervention can prevent severe nerve damage in SMA, enable lifesaving bone marrow transplants for SCID, and drastically lower infant mortality in SCD through preventive measures. The IVDR-approved test provides a ready-to-use solution that integrates into existing laboratory workflows. It runs on established LightCycler systems, making it accessible for private and academic hospital laboratories across Europe.

Yahoo Finance
Sep 13th, 2026
Roche's Tam-Peli cuts death risk by 54% in Chinese SCLC trial, global phase III studies planned

Roche's collaborator MediLink has announced positive phase III results for tambotatug pelitecan (Tam-Peli) in Chinese patients with relapsed small-cell lung cancer. The TAISHAN-302 trial showed Tam-Peli reduced the risk of death by 54% compared to topotecan, with median overall survival of 13.3 versus 9.4 months. The antibody-drug conjugate also demonstrated superior progression-free survival (7.4 versus 2.8 months) and objective response rates (59.1% versus 9.7%). China's National Medical Products Administration has accepted the New Drug Application for filing. Roche is developing and commercialising Tam-Peli outside mainland China, Hong Kong and Macau, with plans to rapidly initiate global trials. The therapy has received Breakthrough Therapy Designations from both the US FDA and China CDE for relapsed small-cell lung cancer.